Evercore resumes coverage of Becton Dickinson, sees steadier growth ahead

Becton Dickinson and Co

04/05/2026 12:56

** Evercore ISI resumes coverage of medical device maker Becton Dickinson BDX.N with "outperform" rating and PT of $180

** Brokerage says BDX is in "transition year", with reported growth hit by temporary issues, including its Alaris infusion pump business, vaccines and pricing pressure in China

** Says "a series of transitory headwinds masking a more stable underlying growth profile"; adds co is growing mid-single-digits on an underlying basis

** Says BDX management has clearly laid out expected pressures in FY26–27, which it believes reduces the risk of negative surprises

** Brokerage points to growth in areas such as biologics-related products, pharmacy automation and patient monitoring, which "should help investors in getting comfortable around mid-single-digit growth going forward"

** 7 of 17 brokerages rate the stock "buy" or higher, and 10 "hold"; their median PT is $198

** As of last close, BDX down 2.1% YTD

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))